Supplementary Materials: Curcuminoids as EBV lytic activators for adjuvant treatment in EBV-positive carcinomas

Octavia Ramayanti, Mitch Brinkkemper, Sandra A.W.M Verkuijlen, Leni Ritmaleni, Mei Lin Go, Jaap M. Middeldorp

**Figure S1.** Curcuminoids induced weak EBV lytic reactivation at low (10 nM) concentrations.

**Figure S2.** Representative immunofluorescence images of C666.1 cells treated by hit compounds (41, EF24) alone or in combination with GCB+VPA. (A). C666.1 expressed Zebra and EA-D lytic proteins upon EF24 treatment alone or in combination with GCB+VPA. (B). C666.1 expressed Zebra and EA-D lytic proteins upon 41 treatment alone or in combination with GCB+VPA. Increased number of cells expressing Zebra and EA-D lytic proteins upon co-treatment with EF24, GCB+VPA (left panel) or with 41, GCB+VPA (right panel) were shown.

**Figure S3.** Pre-treatment with curcuminoid inhibits EBV lytic cycle induced by CLVA regimen. C666.1 cells were treated with hit compounds (41, EF24) 24 h before and after GCB+VPA administration. The cells were collected after 96 h followed by immunoblot detection of Zebra and EA-D proteins. Treatment with hit compounds or GCB+VPA alone for 96 h were included for comparison. When administered simultaneously with CLVA regimen, hit compounds (41, EF24) synergistically induced EBV reactivation. Curcuminoid antagonized the lytic induction effect of GCB+VPA when administered 24 h prior GCB+VPA treatment.